Cellusion Inc., a deep tech start-up developing a novel cell therapy, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to our regenerative medicine product “iPS cell-derived corneal endothelial cell substitute” for the treatment of bullous keratopathy.
